GeneDx Study Shows $80K Per Child Savings with Exome/Genome Testing
Event summary
- GeneDx's SAVES-Kids study found $80K average cost savings per child with neurodevelopmental disorders after exome/genome testing.
- Children with epilepsy saw a 61% reduction in healthcare costs, while those with DD/ID had a 19% reduction.
- Study presented at ACMG Annual Meeting on March 11, 2026, showing fewer hospitalizations and ER visits post-testing.
- GeneDx Infinity dataset combines over 1 million exomes/genomes to drive precision medicine.
The big picture
The study provides real-world validation for genomic testing's role in reducing healthcare costs while improving outcomes for neurodevelopmental disorders. This aligns with broader industry shifts toward value-based care and earlier diagnostic interventions. GeneDx's position as the leader in rare disease diagnostics is reinforced by its proprietary dataset, which gives it a competitive edge in driving precision medicine adoption.
What we're watching
- Adoption Pace
- How quickly payors and health systems will integrate early exome/genome testing into standard care protocols.
- Medicaid Impact
- Whether the demonstrated cost savings in Medicaid populations will accelerate policy changes for broader coverage.
- Competitive Positioning
- GeneDx's ability to maintain leadership as more players enter the rare disease diagnostics space with similar economic evidence.
Related topics